bioAffinity Technologies, Inc. (BIAF)
- Previous Close
2.4100 - Open
2.3200 - Bid 2.3500 x 100
- Ask 2.4500 x 100
- Day's Range
2.3200 - 2.4299 - 52 Week Range
0.9550 - 3.6200 - Volume
94,848 - Avg. Volume
230,109 - Market Cap (intraday)
27.289M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
www.bioaffinitytech.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BIAF
Performance Overview: BIAF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIAF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIAF
Valuation Measures
Market Cap
27.29M
Enterprise Value
26.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.19
Price/Book (mrq)
5.62
Enterprise Value/Revenue
10.28
Enterprise Value/EBITDA
-3.41
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.85%
Return on Equity (ttm)
-99.85%
Revenue (ttm)
2.53M
Net Income Avi to Common (ttm)
-7.94M
Diluted EPS (ttm)
-0.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.82M
Total Debt/Equity (mrq)
32.51%
Levered Free Cash Flow (ttm)
-3.61M